Page 5 of 15
The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast can...
The editors of Hereditary Cancer in Clinical Practice would like to thank all our reviewers who have contributed to the journal in 2015.
Since the identification of BRCA1 there has only ever been described two bi-allelic mutation carriers, one of whom was subsequently shown to be a mono-allelic carrier. The second patient diagnosed with two BRCA1 ...
The Correction to this article has been published in Hereditary Cancer in Clinical Practice 2022 20:20
Mutations in the BRCA1, BRCA2 and PALB2 genes are well-established risk factors for the development of breast and/or ovarian cancer. The frequency and spectrum of mutations in these genes has not yet been exam...
Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and ...
Gastric cancer (GC) is part of the spectrum of diseases linked to BRCA1 and BRCA2 mutations that increase the risk of breast and ovarian cancer. Data suggesting an increased risk of developing GC among BRCA1 and
Breast cancer (BC) is an important public health problem worldwide. In Brazil, breast cancer is the most frequently diagnosed tumor and the leading cause of cancer death in women. Hereditary cancer represents ...
The role of germline mutations in BRCA1 and BRCA2 genes in the risk of the development of ovarian cancer is clinically well established. BRCA1/2 testing seems to have increasing role in clinical management in pat...
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
This article is part of a Supplement: Volume 13 Supplement 2
Germ-line mutations in several genes, such as BRCA1 and BRCA2, are known to increase the risk of breast cancer. These heritable mutations are unequally represented among populations with different ethnic backgrou...
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
This article is part of a Supplement: Volume 13 Supplement 1
Genetic screening in families with high risk to develop colorectal cancer (CRC) prevents incurable disease and permits personalized therapeutic and follow-up strategies. The advancement of next-generation sequ...
Screening for BRCA 1 and BRCA 2 mutations has long moved from the research lab to the clinic as a routine clinical genetic testing. BRCA molecular alteration pattern varies among ethnic groups which makes it a...
The association of germline mutations in the breast cancer susceptibility gene 1 (BRCA1) and the breast cancer susceptibility gene 2 (BRCA2) with the development of breast and ovarian cancers have been widely res...
Approximately 30 % of all breast cancer is at least partly attributed to hereditary factors. Familial breast cancer is often inherited in the context of cancer syndromes. The most commonly mutated genes are BR...
Common genetic variants have been shown to modify BRCA1 penetrance. The aim of this study was to validate these reports in a special cohort of Norwegian BRCA1 mutation carriers that were selected for their extrem...
Pancreatic cancer (PancCa) is recognized as a component of many well-described hereditary cancer syndromes. Minimal research has focused on patient needs and experiences living with this risk.
Patients with Lynch Syndrome are at high risk for developing a variety of cancers including cancers of the colon or rectum, small bowel, stomach, uterus, renal pelvis, ureter, biliary tract, ovaries, brain and...
Advancements in genomic testing have led to the identification of single nucleotide polymorphisms (SNPs) associated with prostate cancer. The clinical utility of SNP tests to evaluate prostate cancer risk is u...
Women who carry a mutation for Lynch syndrome face complex decisions regarding strategies for managing their increased cancer risks. At present, there is limited understanding of the factors influencing women’...
Citation Impact
2.164 - 2-year Impact Factor (2021)
2.089 - 5-year Impact Factor (2021)
0.850 - Source Normalized Impact per Paper (SNIP)
0.546 - SCImago Journal Rank (SJR)
Speed
48 days to first decision for all manuscripts (Median)
66 days to first decision for reviewed manuscripts only (Median)
Usage
237,887 Downloads (2021)
133 Altmetric mentions (2021)
Hereditary Cancer in Clinical Practice